News | January 04, 2012

Gene Analysis Helps Identify Basis of Rare Infant Heart Disorder

January 4, 2012 - A study reported in the current issue of Pediatric and Developmental Pathology compares cardiac tissue from 12 patients with histiocytoid cardiomyopathy (HC) and 12 age-matched controls. Researchers found differences in gene expression that could indicate a predisposition for HC.

HC typically occurs in the first two years of life. It affects females three times more often than males, leading to the theory that it is an X chromosome-linked disorder, with prenatal death occurring in males. Eighty percent of the cases occur in whites 15 percent in blacks and 3 percent in Latin Americans. It is very rare in those of Asian heritage.

A worldwide registry of HC was started in 1999, attempting to identify the gene responsible for the fatal disorder. These data have shown a family tendency for HC.

The gene analysis undertaken in the current study found decreased protein expression, or downregulation, in two sets of genes aligned sequentially along the genome. This offers several genes as candidates for the mutation, possibly predisposing individuals to HC.

The downregulation of a particular gene could result in reduced survival of cardiac myocytes, leading to cardiac failure during a baby’s development. These candidate genes will now offer a starting point for further research into inherited patterns of mutation. Utilizing the HC registry, researchers will seek to confirm the findings of this study and to collect and analyze blood from parents and siblings of HC patients in an effort to further expose the inheritance pattern.

 Full text of the article, “Identification of Candidate Genes for Histiocytoid Cardiomyopathy (HC) Using Whole Genome Expression Analysis: Analyzing Material from the HC Registry,Pediatric and Developmental Pathology, Vol. 14, No. 5, 2011, is available at http://www.pedpath.org/doi/full/10.2350/10-05-0826-OA.1

For more information: www.pedpath.org

 


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now